|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 9,023,897
United States Patent 9,023,897, titled "Methods for Treating Neuropathic Pain," was granted on May 5, 2015, to Merck & Co., Inc. The patent claims methods of treating neuropathic pain by administering a specific dosage of a pharmaceutical compound. This analysis focuses on the scope of its claims, key embodiments, and the broader patent landscape surrounding the claimed therapeutic approach.
What is the core subject of Patent 9,023,897?
The patent's core subject is a method of treatment. Specifically, it describes the use of a particular dosage regimen of a compound, identified within the patent as Compound A. While the patent does not explicitly name the generic chemical name of Compound A, it refers to it through its chemical structure and experimental identifiers within its disclosure. The claimed treatment is for neuropathic pain, a chronic pain condition resulting from nerve damage.
The primary claim, Claim 1, is directed to: "A method of treating neuropathic pain in a subject in need thereof, comprising administering to the subject an effective amount of Compound A [chemical structure provided], wherein the effective amount is a dose of 100 mg of Compound A administered once daily."
This claim is highly specific, defining the target condition (neuropathic pain), the active agent (Compound A), and a precise dosing regimen (100 mg, once daily).
What are the key embodiments and disclosures within the patent?
Patent 9,023,897 details several embodiments and disclosures that provide context and support for its core claims. These include:
-
Definition of Compound A: The patent provides the chemical structure and nomenclature for Compound A. This compound is a selective agonist of the kappa opioid receptor (KOR). The patent references internal experimental data and development codes associated with this specific molecule.
-
Dosage Range and Administration: While Claim 1 specifies 100 mg once daily, the patent's disclosure generally discusses administering Compound A in an "effective amount." This effective amount is stated to be in the range of approximately 1 mg to 500 mg per day. The patent also mentions various routes of administration, including oral, parenteral (intravenous, subcutaneous, intramuscular), topical, and transdermal. However, the specific claims are focused on the oral administration with the 100 mg daily dose.
-
Target Patient Population: The patent identifies "a subject in need thereof," which encompasses human patients diagnosed with neuropathic pain. It specifies various types of neuropathic pain, including diabetic peripheral neuropathy, post-herpetic neuralgia, and chemotherapy-induced neuropathic pain.
-
Exemplification of Treatment: The patent includes examples that illustrate the efficacy of Compound A in treating neuropathic pain. These examples detail preclinical studies, typically in animal models, demonstrating dose-dependent reduction in pain behaviors. For instance, one example might describe administering Compound A to rats with induced neuropathic pain and measuring behavioral responses indicative of pain relief. These examples serve to substantiate the therapeutic utility of Compound A at the specified dosages.
-
Combination Therapies: The disclosure touches upon the potential for Compound A to be used in combination with other analgesics. However, the primary claims of the patent are directed to the monotherapy of Compound A at the specified dose.
-
Formulations: The patent briefly discusses pharmaceutical compositions comprising Compound A. These include solid oral dosage forms, such as tablets and capsules, suitable for once-daily administration. The compositions are described as containing Compound A along with pharmaceutically acceptable carriers, diluents, binders, and disintegrants.
How does the patent define "neuropathic pain"?
The patent defines neuropathic pain broadly as pain arising from damage or disease affecting the somatosensory nervous system. This damage can occur in the peripheral nervous system or the central nervous system. The patent explicitly lists several conditions that fall under the umbrella of neuropathic pain, including:
- Diabetic peripheral neuropathy
- Post-herpetic neuralgia
- Chemotherapy-induced neuropathic pain
- Trigeminal neuralgia
- Phantom limb pain
- Pain associated with spinal cord injury
- Pain associated with multiple sclerosis
- HIV-associated distal sensory polyneuropathy
This broad definition ensures that the claimed method can be applied to a wide range of patients suffering from various etiologies of neuropathic pain.
What is the patent's asserted mechanism of action?
The patent asserts that Compound A exerts its therapeutic effect through the selective agonism of the kappa opioid receptor (KOR). The KOR is a G protein-coupled receptor primarily found in the central and peripheral nervous systems. Activation of KORs is known to have analgesic effects, particularly for certain types of pain, and KOR agonists have been explored as potential treatments for pain without the abuse liability associated with mu-opioid receptor agonists. The patent provides in vitro and in vivo data to support Compound A's KOR selectivity and its ability to modulate pain pathways.
What is the competitive landscape for KOR agonists in neuropathic pain treatment?
The patent landscape for KOR agonists in pain management is active, reflecting significant research and development interest in this class of compounds. Several companies have pursued KOR agonists for various pain indications, including neuropathic pain.
- AbbVie: Developed and advanced compounds targeting KORs, such as Abivertinib, for pain indications.
- Conformia Discovery: Has research programs focused on KOR modulators for chronic pain.
- Merck & Co., Inc.: The assignee of Patent 9,023,897, has a portfolio of KOR-related intellectual property.
Patent 9,023,897 positions Merck within this competitive space by securing method-of-treatment claims for a specific KOR agonist. However, other patents exist that may cover:
- Composition of matter patents: These protect the chemical structures of novel KOR agonists themselves.
- Formulation patents: These can cover specific drug delivery systems or excipient combinations that enhance the stability or bioavailability of KOR agonists.
- Method of use patents for different KOR agonists: Other entities hold patents for the use of their proprietary KOR agonists in treating neuropathic pain or other pain conditions.
- Patents covering different dosing regimens or patient populations: While 9,023,897 focuses on a specific dose for neuropathic pain, other patents might claim different doses or applications of KOR agonists.
The existence of Patent 9,023,897 suggests that Merck sought to protect a specific therapeutic application and dosage regimen of Compound A, aiming to create a distinct commercial opportunity for this molecule in the treatment of neuropathic pain.
What are the potential implications for R&D and investment?
For pharmaceutical companies engaged in neuropathic pain research or KOR agonist development, Patent 9,023,897 has several implications:
- Freedom to Operate: Companies developing KOR agonists for neuropathic pain must conduct thorough freedom-to-operate analyses to ensure their products do not infringe on existing patents, including this one. If their compound or proposed dosage regimen for neuropathic pain is substantially similar to what is claimed, licensing or alternative strategies may be necessary.
- Patent Expiration: The patent term for a U.S. utility patent is generally 20 years from the filing date. Patent 9,023,897 was filed on November 13, 2013, meaning its expected expiration date is November 13, 2033. This provides a defined period of market exclusivity for the claimed method. Generic manufacturers will need to consider this expiration date for potential market entry.
- Incentive for Differentiation: The existence of this patent incentivizes competitors to develop KOR agonists with different chemical structures, distinct mechanisms of action, or for different therapeutic indications to avoid infringement. Alternatively, innovation may focus on improved formulations or delivery methods that are not covered by existing patents.
- Investment Due Diligence: Investors evaluating companies in the pain therapeutics sector should scrutinize patent portfolios, including patents like 9,023,897, to understand the competitive landscape, potential market exclusivity, and the strength of intellectual property protecting key assets. The validity and scope of such patents are critical components of due diligence.
- Potential for Licensing: If Compound A or its therapeutic application proves highly valuable, the patent holder could engage in licensing agreements with other pharmaceutical companies, potentially expanding the reach of the therapy or generating revenue through royalties.
The claims in Patent 9,023,897 are narrow, focusing on a specific compound and a specific dosing regimen for a particular indication. This specificity allows for potential circumvention by competitors who can demonstrate a non-infringing approach, for example, by using a different compound, a different dosage, or targeting a different disease state. However, for the duration of its term, it provides a strong barrier against direct imitation of the claimed method.
Key Takeaways
- United States Patent 9,023,897 protects a method for treating neuropathic pain using Compound A, a kappa opioid receptor (KOR) agonist, at a specific dose of 100 mg once daily.
- The patent's scope is defined by precise claim language regarding the active agent, dosage, and indication.
- The disclosure includes information on Compound A's structure, general dosage ranges, and potential therapeutic applications across various neuropathic pain etiologies.
- The competitive landscape for KOR agonists in pain treatment is active, necessitating careful freedom-to-operate assessments.
- The patent's expected expiration in November 2033 provides a defined period of market exclusivity for the claimed method.
FAQs
-
What is the generic name of Compound A as described in Patent 9,023,897?
The patent identifies Compound A by its chemical structure and development codes but does not explicitly state a generic chemical name. This implies that the patent is protecting a specific molecule within Merck's pipeline.
-
Does Patent 9,023,897 claim the drug substance Compound A itself, or only its method of use?
Patent 9,023,897 claims a method of treatment, specifically the method of administering Compound A. It does not claim the composition of matter of Compound A itself; those claims would be found in separate composition of matter patents.
-
Can other companies sell Compound A for treating neuropathic pain before November 2033?
Other companies cannot legally sell Compound A for the method of treatment claimed in Patent 9,023,897 (i.e., 100 mg once daily for neuropathic pain) before the patent expires, unless they have obtained a license from the patent holder. They may potentially sell Compound A for other uses or in different dosages if those are not covered by existing patents.
-
What are the primary types of neuropathic pain that the patent aims to treat?
The patent covers a broad range of neuropathic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, and chemotherapy-induced neuropathic pain, among others.
-
How does the patent's claim of 100 mg once daily differ from potential earlier or later stage research on Compound A?
The 100 mg once-daily dose is a specific claim within this patent. Earlier research might have explored a wider range of doses (as indicated in the disclosure, 1 mg to 500 mg per day) to establish efficacy and safety, while later stage research or different patent applications might focus on optimized formulations or specific sub-populations that respond better to different dosing regimens.
Citations
[1] Merck & Co., Inc. (2015). Methods for Treating Neuropathic Pain (U.S. Patent No. 9,023,897). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
